Stocktoria
Autolus Therapeutics plc AUTL
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-06-22
Autolus Therapeutics plc financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $75.4M | $10.1M | $1.7M | — | — |
| R&D expense | $117.7M | $138.4M | $130.5M | $117.4M | $110.8M |
| SG&A expense | $131.9M | $101.7M | $46.7M | — | — |
| Operating income | -$270.5M | -$241.4M | -$179.7M | -$143.4M | -$141.1M |
| Interest expense | $36.7M | $9.3M | $45.1M | $8.9M | $1.1M |
| Income tax | $2.0M | $1.5M | -$19,000 | $272,000 | $58,000 |
| Net income | -$287.5M | -$220.7M | -$208.4M | -$148.8M | -$142.1M |
| EPS (diluted) | $-1.08 | $-0.86 | $-1.20 | $-1.57 | $-1.97 |
| Operating cash flow | -$283.6M | -$206.3M | -$145.6M | -$112.3M | -$117.9M |
| Free cash flow | -$302.6M | -$228.3M | -$156.6M | -$123.1M | -$126.7M |
| Cash & equivalents | $104.1M | $227.4M | $239.6M | $382.4M | $310.3M |
| Inventory | $33.2M | $4.1M | $0 | — | — |
| Total assets | $589.1M | $782.7M | $375.4M | $490.3M | $405.6M |
| Total liabilities | $410.9M | $355.4M | $263.9M | $191.6M | $92.2M |
| Shareholders' equity | $178.1M | $427.3M | $111.5M | $298.7M | $313.3M |
Source: SEC EDGAR filings · CIK 0001730463 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.